



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





NTRK 1, 2, 3 FISH Panel

Alternative Name

NTRK FISH Panel

Methodology

FISH

Test Description

Probes: NTRK1 (1q23.1), NTRK2 (9q21.33), NTRK3 (15q25.3)

Disease(s): Various solid tumors.

Clinical Significance

The NTRK 1, 2, 3 FISH Panel provides simultaneous analysis of NTRK1, NTRK2, and NTRK3 for gene rearrangements (fusions) to identify TRK-inhibitor therapy and clinical trial options using break-apart probes. This panel is useful for screening solid tumors. Approximately 1% of solid tumors overall will have a positive FISH panel result. FISH-negative results in any tumor type may be confirmed with the [NTRK NGS Fusion Profile](#). [Pan-TRK IHC testing](#) is also available to screen most tumors with low fusion frequencies. See also [NTRK3 FISH](#) for tumors with very high NTRK3 fusion frequencies. Fusion partners of the NTRK gene are not identified by this FISH panel but are identified by the NTRK NGS Fusion Profile.

Specimen Requirements

- **Bone marrow aspirate:** N/A
- **Peripheral blood:** N/A
- **Fresh, unfixed tissue:** N/A.
- **Fluids:** N/A
- **Paraffin block:** Send paraffin block. Also send circled H&E slide for tech-only (required).
- **Cut slides:** H&E slide (required) plus 5 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

88377x3 manual or 88374x3 automated

New York Approved

Yes

Level of Service

Global, Technical

Turnaround Time

3-5 days

References

1. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*. 2018;15:731-747.
2. Chen Y, Chi P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. *J Hematol Oncol*. 2018;11:78.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 050124